Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
Post-ASH 2022 MDS Highlights
12 January 2023 | Virtual Meeting
Expert-led presentations & discussions on key abstracts in myelodysplastic syndromes (MDS) from ASH 2022
The Post-ASH 2022 MDS Highlights virtual workshop was held on 12 January 2022. The program covered the latest in MDS and featured a series of short presentations from invited experts on selected abstracts from the 64th ASH Annual Meeting with interactive panel discussions after each session.
Session 1: prognostic factors in MDS
Phase I results of SX-682 in patients with hypomethylating agent failure MDS
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Real-world validation of IPSS-M for MDS
Matteo Della Porta Humanitas Research Hospital, Milan, Italy
Session 1 panel discussion
Session 2: classification of MDS and disease characteristics
Validation of 2022 WHO and ICC classifications
Somedeb Ball H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
MDS in Latin America - results from a novel international registry: Re-Glam
Marcelo Iastrebner Sanatorio Sagrado Corazón, Buenos Aires, Argentina
Panel discussion 2
Content to be uploaded soon
Session 3: lower risk MDS
Synergistic activity of luspatercept & ESAs for treatment of anemia in LR-MDS
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Luspatercept for HMA and len-treated patients with LR-MDS: real-world data
Rami Komrokji H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Clinical & biological effects of canakinumab in LR-MDS: Phase II trial
Simona Colla University of Texas MD Anderson Cancer Center, Houston, TX, United States
ASTX727-03: Phase I study evaluating ASTX727 low-dose in LR-MDS
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Panel discussion 3
MEDALIST trial: OS and PFS of patients following treatment with luspatercept
Valeria Santini University of Florence, Florence, Italy
Sintra-REV: len vs placebo in non-transfusion dependent del(5q) LR-MDS
María Díez Campelo University of Salamanca, Salamanca, Spain
IMerge: imetelstat in patients with transfused non-del(5q) LR-MDS R/R to ESAs
Uwe Platzbecker University Hospital in Leipzig, Leipzig, Germany
Panel discussion 4
Session 4: higher risk MDS
Primary results of Stimulus-MDS1: sabatolimab added to HMAs in HR-MDS
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Results of Phase II multicenter trial of ruxolitinib in symptomatic CMML
Eric Padron Moffitt Cancer Center, Tampa, FL, United States
Panel discussion 5
